This is a preprint.
How to Build the Virtual Cell with Artificial Intelligence: Priorities and Opportunities
- PMID: 39398201
- PMCID: PMC11468656
How to Build the Virtual Cell with Artificial Intelligence: Priorities and Opportunities
Update in
-
How to build the virtual cell with artificial intelligence: Priorities and opportunities.Cell. 2024 Dec 12;187(25):7045-7063. doi: 10.1016/j.cell.2024.11.015. Cell. 2024. PMID: 39672099 Free PMC article.
Abstract
The cell is arguably the most fundamental unit of life and is central to understanding biology. Accurate modeling of cells is important for this understanding as well as for determining the root causes of disease. Recent advances in artificial intelligence (AI), combined with the ability to generate large-scale experimental data, present novel opportunities to model cells. Here we propose a vision of leveraging advances in AI to construct virtual cells, high-fidelity simulations of cells and cellular systems under different conditions that are directly learned from biological data across measurements and scales. We discuss desired capabilities of such AI Virtual Cells, including generating universal representations of biological entities across scales, and facilitating interpretable in silico experiments to predict and understand their behavior using Virtual Instruments. We further address the challenges, opportunities and requirements to realize this vision including data needs, evaluation strategies, and community standards and engagement to ensure biological accuracy and broad utility. We envision a future where AI Virtual Cells help identify new drug targets, predict cellular responses to perturbations, as well as scale hypothesis exploration. With open science collaborations across the biomedical ecosystem that includes academia, philanthropy, and the biopharma and AI industries, a comprehensive predictive understanding of cell mechanisms and interactions has come into reach.
Conflict of interest statement
Competing interests C.B. and A. R. are employees of Genentech, a member of the Roche Group. A.R. has equity in Roche. A.R. was a co-founder and equity holder of Celsius Therapeutics, and is an equity holder in Immunitas. Until July 31, 2020 A.R. was an S.A.B. member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. A.R. is a named inventor on multiple filed patents related to single cell and spatial genomics, including for scRNA-seq, spatial transcriptomics, Perturb-Seq, compressed experiments, and PerturbView. E.L. is an advisor for the Chan-Zuckerberg Initiative Foundation. N.J.S. is an employee of EvolutionaryScale, PBC.
Figures


References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources